PL3348635T3 - Nowy mutant albuminy krwi ludzkiej - Google Patents

Nowy mutant albuminy krwi ludzkiej

Info

Publication number
PL3348635T3
PL3348635T3 PL16844430T PL16844430T PL3348635T3 PL 3348635 T3 PL3348635 T3 PL 3348635T3 PL 16844430 T PL16844430 T PL 16844430T PL 16844430 T PL16844430 T PL 16844430T PL 3348635 T3 PL3348635 T3 PL 3348635T3
Authority
PL
Poland
Prior art keywords
serum albumin
human serum
novel human
albumin mutant
mutant
Prior art date
Application number
PL16844430T
Other languages
English (en)
Inventor
Kenichi Takahashi
Aya YOSHIOKA
Hideto Morimoto
Masafumi Kinoshita
Original Assignee
Jcr Pharmaceuticals Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jcr Pharmaceuticals Co., Ltd. filed Critical Jcr Pharmaceuticals Co., Ltd.
Publication of PL3348635T3 publication Critical patent/PL3348635T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76—Albumins
    • C07K14/765—Serum albumin, e.g. HSA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/27—Growth hormone [GH], i.e. somatotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/61—Growth hormone [GH], i.e. somatotropin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C12N5/12—Fused cells, e.g. hybridomas
    • C12N5/16—Animal cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/10—Plasmid DNA
    • C12N2800/106—Plasmid DNA for vertebrates
    • C12N2800/107—Plasmid DNA for vertebrates for mammalian

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Endocrinology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • General Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
PL16844430T 2015-09-08 2016-09-08 Nowy mutant albuminy krwi ludzkiej PL3348635T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2015177093 2015-09-08
EP16844430.5A EP3348635B1 (en) 2015-09-08 2016-09-08 Novel human serum albumin mutant
PCT/JP2016/076438 WO2017043569A1 (ja) 2015-09-08 2016-09-08 新規なヒト血清アルブミン変異体

Publications (1)

Publication Number Publication Date
PL3348635T3 true PL3348635T3 (pl) 2021-09-27

Family

ID=58239798

Family Applications (1)

Application Number Title Priority Date Filing Date
PL16844430T PL3348635T3 (pl) 2015-09-08 2016-09-08 Nowy mutant albuminy krwi ludzkiej

Country Status (16)

Country Link
US (3) US10654912B2 (pl)
EP (3) EP4374913A3 (pl)
JP (4) JP6886920B2 (pl)
KR (1) KR102360744B1 (pl)
CN (2) CN114591445B (pl)
AU (3) AU2016319540B2 (pl)
CA (2) CA3183289A1 (pl)
CY (1) CY1123997T1 (pl)
DK (1) DK3348635T3 (pl)
ES (1) ES2861059T3 (pl)
HR (1) HRP20210635T1 (pl)
HU (1) HUE053937T2 (pl)
PL (1) PL3348635T3 (pl)
PT (1) PT3348635T (pl)
SI (1) SI3348635T1 (pl)
WO (1) WO2017043569A1 (pl)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017165713A (ja) * 2016-03-14 2017-09-21 Ｊｃｒファーマ株式会社 血清アルブミン−２０ｋ成長ホルモン融合タンパク質
JP2020002130A (ja) 2018-06-25 2020-01-09 Ｊｃｒファーマ株式会社 蛋白質含有水性液剤
CN109734816A (zh) * 2019-03-12 2019-05-10 王大勇 一种基因重组人促皮质素与白蛋白的融合蛋白及表达方法
EP4047006A4 (en) * 2019-10-17 2023-11-01 JCR Pharmaceuticals Co., Ltd. Method for producing fusion protein of serum albumin and growth hormone
CN114728043B (zh) * 2019-10-30 2024-04-16 Jcr制药股份有限公司 含有血清白蛋白与生长激素的融合蛋白的水性药物组合物
WO2021133822A1 (en) 2019-12-24 2021-07-01 Juvena Therapeutics,Inc. Regenerative polypeptides and uses thereof
CN113430227A (zh) * 2020-03-23 2021-09-24 佛山汉腾生物科技有限公司 制备稳定细胞池的方法、蛋白表达方法及试剂盒
CA3223707A1 (en) 2021-06-21 2022-12-29 Hanadie Yousef Regenerative polypeptides and uses thereof
CN114133458B (zh) * 2021-12-08 2023-11-14 福州大学 一种在人血清白蛋白内部融合多肽的方法
WO2024080305A1 (ja) * 2022-10-11 2024-04-18 Ｊｃｒファーマ株式会社 血清アルブミンと生理活性を有する蛋白質との融合蛋白質

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2650598B1 (fr) 1989-08-03 1994-06-03 Rhone Poulenc Sante Derives de l'albumine a fonction therapeutique
FR2686900B1 (fr) 1992-01-31 1995-07-21 Rhone Poulenc Rorer Sa Nouveaux polypeptides ayant une activite de stimulation des colonies de granulocytes, leur preparation et compositions pharmaceutiques les contenant.
FR2686899B1 (fr) 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
JP3398427B2 (ja) * 1992-09-09 2003-04-21 三井化学株式会社 成長ホルモンの生産方法
NZ286884A (en) * 1995-06-29 1997-12-19 Mitsui Chemicals Inc Use of 20 kd human growth hormone in hrt, increasing serum igf-1 levels and stimulating lipolysis
GB9526733D0 (en) * 1995-12-30 1996-02-28 Delta Biotechnology Ltd Fusion proteins
WO1997024450A1 (en) * 1996-01-02 1997-07-10 Paik Kye Hyung Method for immunizing and treating human cells in animal organs maintained in vitro
US6123775A (en) 1999-06-30 2000-09-26 Lam Research Corporation Reaction chamber component having improved temperature uniformity
AU2001261024A1 (en) * 2000-04-12 2001-10-30 Delta Biotechnology Limited Albumin fusion proteins
EP2277910A1 (en) 2001-12-21 2011-01-26 Human Genome Sciences, Inc. Albumin fusion proteins
NZ534492A (en) 2002-02-07 2009-10-30 Novozymes Delta Ltd Albumin-fused kunitz domain peptides
GB0217347D0 (en) 2002-07-26 2002-09-04 Univ Edinburgh Novel albumins
CN1980687B (zh) * 2004-02-09 2015-05-13 人类基因科学公司 清蛋白融合蛋白
EP1729795B1 (en) 2004-02-09 2016-02-03 Human Genome Sciences, Inc. Albumin fusion proteins
US7998930B2 (en) 2004-11-04 2011-08-16 Hanall Biopharma Co., Ltd. Modified growth hormones
CN1313494C (zh) * 2005-08-29 2007-05-02 中国人民解放军军事医学科学院生物工程研究所 一种具有促增长作用的融合蛋白及其编码基因与应用
EP2054437A2 (en) 2006-08-07 2009-05-06 Teva Biopharmaceuticals USA, Inc. Albumin-insulin fusion proteins
JP4983148B2 (ja) 2006-08-18 2012-07-25 ニプロ株式会社 糖鎖含有アルブミン、その製造方法およびその用途
US7773341B2 (en) 2007-07-03 2010-08-10 Headway Technologies, Inc. Laminated film for head applications
US7943570B2 (en) * 2007-10-16 2011-05-17 Nipro Corporation Sugar chain-containing albumin, production method thereof and use thereof
CN101429240A (zh) * 2007-11-06 2009-05-13 尼普洛株式会社 一种含有糖链的白蛋白、其制备方法及其用途
CA2611540C (en) * 2007-11-09 2017-05-30 Nipro Corporation Sugar chain-containing albumin as a drug carrier to the liver
JP5727459B2 (ja) * 2009-04-22 2015-06-03 アルテオゼン， インクＡｌｔｅｏｇｅｎ， Ｉｎｃ 体内持続性を維持することにより体内半減期が増加したタンパク質またはペプチド融合体
EP2461831B1 (en) 2009-08-06 2018-11-21 Novo Nordisk Health Care AG Growth hormones with prolonged in-vivo efficacy
CN118767115A (zh) 2010-01-22 2024-10-15 诺沃—诺迪斯克保健股份有限公司 体内功效延长的生长激素
CN102336828B (zh) * 2010-07-26 2013-06-26 中国医学科学院基础医学研究所 一种多发性骨髓瘤特异性蛋白及其专用检测试剂盒
KR101890446B1 (ko) 2010-11-08 2018-08-21 제이씨알 파마 가부시키가이샤 신규 발현 벡터
WO2013161958A1 (ja) 2012-04-27 2013-10-31 日本ケミカルリサーチ株式会社 新規な発現ベクター

Also Published As

Publication number Publication date
SI3348635T1 (sl) 2021-08-31
CN114591445A (zh) 2022-06-07
DK3348635T3 (da) 2021-03-01
CN107949638A (zh) 2018-04-20
KR20180042432A (ko) 2018-04-25
HUE053937T2 (hu) 2021-08-30
CN107949638B (zh) 2022-05-13
WO2017043569A1 (ja) 2017-03-16
HK1247244A1 (zh) 2018-09-21
HRP20210635T1 (hr) 2021-08-20
CY1123997T1 (el) 2022-05-27
EP3348635B1 (en) 2021-02-17
US20210269507A1 (en) 2021-09-02
EP3845644C0 (en) 2024-04-24
KR102360744B1 (ko) 2022-02-08
CA2996672A1 (en) 2017-03-16
JP2021141893A (ja) 2021-09-24
EP3348635A1 (en) 2018-07-18
AU2022204463A1 (en) 2022-07-14
JP2024037850A (ja) 2024-03-19
US20200247872A1 (en) 2020-08-06
AU2021212110B2 (en) 2022-07-14
ES2861059T3 (es) 2021-10-05
PT3348635T (pt) 2021-03-15
EP4374913A2 (en) 2024-05-29
US11046751B2 (en) 2021-06-29
EP3348635A4 (en) 2019-06-19
JP2022166098A (ja) 2022-11-01
AU2016319540A1 (en) 2018-03-22
EP3845644A1 (en) 2021-07-07
JP6886920B2 (ja) 2021-06-16
US11634474B2 (en) 2023-04-25
JP7403595B2 (ja) 2023-12-22
US10654912B2 (en) 2020-05-19
JP7123216B2 (ja) 2022-08-22
US20180244754A1 (en) 2018-08-30
CN114591445B (zh) 2024-04-23
EP3845644B1 (en) 2024-04-24
AU2022204463B2 (en) 2024-05-02
AU2016319540B2 (en) 2021-08-26
CA2996672C (en) 2023-02-21
JPWO2017043569A1 (ja) 2018-06-28
EP4374913A3 (en) 2024-08-14
AU2021212110A1 (en) 2021-08-26
CA3183289A1 (en) 2017-03-16

Similar Documents

Publication Publication Date Title
GB201502305D0 (en) Protein
GB201502306D0 (en) Protein
HUE053937T2 (hu) Új humánszérumalbumin-mutáns
IL252696A0 (en) protein production
PL3429432T3 (pl) Krzesło
GB201608197D0 (en) Novel proteins
GB201515745D0 (en) Proteins
GB201511787D0 (en) Proteins
GB2558968B (en) G Proteins
ZA201902689B (en) Therapeutic protein
GB201513033D0 (en) Proteins
GB2537527B (en) Chair
DK3462986T3 (en) Balance chair
GB201522610D0 (en) Protein
GB201611139D0 (en) Wheelchair
GB201616715D0 (en) Therapeutic protein
AU201614146S (en) Chair
AU201614142S (en) Chair
AU201614144S (en) Chair
AU201614143S (en) Chair
GB201609236D0 (en) Chair
GB201609230D0 (en) Chair
GB201609227D0 (en) Chair
GB201617737D0 (en) Nida Commercial
AU201612349S (en) Chair